share_log

Goldman Sachs Initiates Coverage On Revance Therapeutics With Buy Rating, Announces Price Target of $33

Benzinga Real-time News ·  Sep 22, 2022 06:21

Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment